US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
US6822267B1
(en)
*
|
1997-08-20 |
2004-11-23 |
Advantest Corporation |
Signal transmission circuit, CMOS semiconductor device, and circuit board
|
CA2391952C
(en)
|
1999-11-23 |
2012-01-31 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
US20030129724A1
(en)
|
2000-03-03 |
2003-07-10 |
Grozinger Christina M. |
Class II human histone deacetylases, and uses related thereto
|
PE20020354A1
(es)
*
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
JP2004509941A
(ja)
|
2000-09-29 |
2004-04-02 |
プロリフィクス リミテッド |
Hdacインヒビターとしてのアミド結合を含むカルバミン酸化合物
|
US7312247B2
(en)
*
|
2001-03-27 |
2007-12-25 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
WO2003032921A2
(en)
|
2001-10-16 |
2003-04-24 |
Sloan-Kettering Institute For Cancer Research |
Treatment of neurodegenerative diseases and cancer of the brain
|
US7402603B2
(en)
*
|
2001-11-06 |
2008-07-22 |
Novartis Ag |
Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
|
RU2320331C2
(ru)
|
2002-03-04 |
2008-03-27 |
МЕРК ЭйчДиЭйСи Рисерч, ЛЛС. |
Способ индукции конечной дифференцировки
|
US7148257B2
(en)
|
2002-03-04 |
2006-12-12 |
Merck Hdac Research, Llc |
Methods of treating mesothelioma with suberoylanilide hydroxamic acid
|
US7456219B2
(en)
|
2002-03-04 |
2008-11-25 |
Merck Hdac Research, Llc |
Polymorphs of suberoylanilide hydroxamic acid
|
ATE399012T1
(de)
|
2002-04-03 |
2008-07-15 |
Topotarget Uk Ltd |
Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
|
WO2003087066A1
(en)
*
|
2002-04-11 |
2003-10-23 |
Sk Chemicals, Co., Ltd. |
α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
|
EP1501489A4
(en)
*
|
2002-04-15 |
2007-11-21 |
Sloan Kettering Inst Cancer |
COMBINATION THERAPY FOR THE TREATMENT OF CANCER
|
WO2003103712A1
(en)
*
|
2002-06-01 |
2003-12-18 |
Novartis Ag |
Combinations comprising epothilones and pharmaceutical uses thereof
|
JP4804004B2
(ja)
*
|
2002-08-20 |
2011-10-26 |
アステラス製薬株式会社 |
関節軟骨細胞外マトリクス分解阻害剤
|
BR0314112A
(pt)
*
|
2002-09-13 |
2005-07-12 |
Univ Virginia Commonwealth |
Combinação de a) n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e b) um inibidor de desacetilase de histona para o tratamento de leucemia
|
US7154002B1
(en)
|
2002-10-08 |
2006-12-26 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
US7250514B1
(en)
|
2002-10-21 |
2007-07-31 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
AU2003280838A1
(en)
*
|
2002-11-19 |
2004-06-15 |
Takeda Pharmaceutical Company Limited |
Indole derivatives as somatostatin agonists or antagonists
|
AU2003296310A1
(en)
|
2002-12-06 |
2004-06-30 |
University Of South Florida |
Histone deacetylase inhibitor enhancement of trail-induced apoptosis
|
US7135493B2
(en)
|
2003-01-13 |
2006-11-14 |
Astellas Pharma Inc. |
HDAC inhibitor
|
WO2004065354A1
(en)
|
2003-01-17 |
2004-08-05 |
Topotarget Uk Limited |
Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors
|
AU2003900608A0
(en)
*
|
2003-02-11 |
2003-02-27 |
Fujisawa Pharmaceutical Co., Ltd. |
Hdac inhibitor
|
AU2003900587A0
(en)
*
|
2003-02-11 |
2003-02-27 |
Fujisawa Pharmaceutical Co., Ltd. |
Hdac inhibitor
|
WO2004076386A2
(en)
|
2003-02-25 |
2004-09-10 |
Topotarget Uk Limited |
Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
|
US7381825B2
(en)
*
|
2003-03-17 |
2008-06-03 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
US20070123580A1
(en)
*
|
2003-05-21 |
2007-05-31 |
Atadja Peter W |
Combination of histone deacetylase inhibitors with chemotherapeutic agents
|
WO2005011598A2
(en)
|
2003-07-31 |
2005-02-10 |
University Of South Florida |
Leukemia treatment method and composition
|
JP2007501775A
(ja)
*
|
2003-08-07 |
2007-02-01 |
ノバルティス アクチエンゲゼルシャフト |
免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
|
CN100536850C
(zh)
*
|
2003-08-08 |
2009-09-09 |
诺瓦提斯公司 |
包含星孢素的组合
|
EP1663194B1
(en)
|
2003-08-26 |
2010-03-31 |
Merck HDAC Research, LLC |
Use of SAHA for treating mesothelioma
|
EP2226072A1
(en)
|
2003-08-29 |
2010-09-08 |
Aton Pharma, Inc. |
Combinations of suberoylanilide hydroxamic acid and antimetbolic agents for treating cancer
|
CN100455564C
(zh)
*
|
2003-09-12 |
2009-01-28 |
深圳微芯生物科技有限责任公司 |
组蛋白去乙酰化酶抑制剂及其药用制剂的制备和应用
|
BRPI0414506A
(pt)
*
|
2003-09-18 |
2006-11-07 |
Novartis Ag |
combinação de um inibidor de histona desacetilase com um ligante de receptor de morte
|
SI1673349T1
(sl)
*
|
2003-09-22 |
2010-10-29 |
S Bio Pte Ltd |
Derivati benzimidazola: priprava in farmacevtske uporabe
|
ATE472534T1
(de)
|
2003-09-22 |
2010-07-15 |
S |
Benzimidazolderivate: herstellung und pharmazeutische anwendungen
|
WO2005027972A2
(en)
*
|
2003-09-23 |
2005-03-31 |
Novartis Ag |
Combination of a vegf receptor inhibitor with a chemotherapeutic agent
|
AR046605A1
(es)
*
|
2003-10-27 |
2005-12-14 |
S Bio Pte Ltd |
Hidroxamatos unidos a biarilo; preparacion y aplicaciones farmaceuticas
|
AU2004296764B2
(en)
|
2003-12-02 |
2011-04-28 |
The Ohio State University Research Foundation |
Zn2+ -chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors
|
EP1541549A1
(en)
|
2003-12-12 |
2005-06-15 |
Exonhit Therapeutics S.A. |
Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
|
WO2005066151A2
(en)
*
|
2003-12-19 |
2005-07-21 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
WO2005065681A1
(en)
*
|
2003-12-19 |
2005-07-21 |
Takeda San Diego, Inc. |
N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
|
US20050197336A1
(en)
*
|
2004-03-08 |
2005-09-08 |
Miikana Therapeutics Corporation |
Inhibitors of histone deacetylase
|
US7345043B2
(en)
*
|
2004-04-01 |
2008-03-18 |
Miikana Therapeutics |
Inhibitors of histone deacetylase
|
KR20080083220A
(ko)
|
2004-04-07 |
2008-09-16 |
노파르티스 아게 |
Iap 억제제
|
CA2574035A1
(en)
*
|
2004-07-19 |
2006-02-23 |
Sandro Belvedere |
Histone deacetylase inhibitors
|
KR20070057822A
(ko)
*
|
2004-08-09 |
2007-06-07 |
아스텔라스세이야쿠 가부시키가이샤 |
히스톤 디아세틸라제 (hdac) 억제제 활성을 갖는히드록시아미드 화합물
|
ITMI20041869A1
(it)
|
2004-10-01 |
2005-01-01 |
Dac Srl |
Nuovi inibitori delle istone deacetilasi
|
US8242175B2
(en)
|
2004-10-01 |
2012-08-14 |
Dac S.R.L. |
Class of histone deacetylase inhibitors
|
US7235688B1
(en)
|
2004-11-04 |
2007-06-26 |
University Of Notre Dame Du Lac |
Process for preparing histone deacetylase inhibitors and intermediates thereof
|
US20070021612A1
(en)
*
|
2004-11-04 |
2007-01-25 |
University Of Notre Dame Du Lac |
Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
|
WO2006066133A2
(en)
*
|
2004-12-16 |
2006-06-22 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
CA2596015A1
(en)
|
2005-02-14 |
2006-08-24 |
Sampath K. Anandan |
Fused heterocyclic compounds useful as inhibitors of histone deacetylase
|
US7666880B2
(en)
*
|
2005-03-21 |
2010-02-23 |
S*Bio Pte Ltd. |
Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
|
CA2937005A1
(en)
|
2005-03-22 |
2006-09-28 |
President And Fellows Of Harvard College |
Treatment of protein degradation disorders
|
GB0509225D0
(en)
|
2005-05-05 |
2005-06-15 |
Chroma Therapeutics Ltd |
Inhibitors of enzymatic activity
|
GB0509223D0
(en)
*
|
2005-05-05 |
2005-06-15 |
Chroma Therapeutics Ltd |
Enzyme inhibitors
|
WO2006122319A2
(en)
*
|
2005-05-11 |
2006-11-16 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
TWI365068B
(en)
|
2005-05-20 |
2012-06-01 |
Merck Sharp & Dohme |
Formulations of suberoylanilide hydroxamic acid and methods for producing same
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
BRPI0613429A2
(pt)
*
|
2005-07-14 |
2009-02-10 |
Takeda San Diego Inc |
inibidores de histona desacetilase
|
WO2007016532A2
(en)
*
|
2005-08-02 |
2007-02-08 |
Novartis Ag |
Mutations and polymorphisms of hdac4
|
EP1912640B1
(en)
|
2005-08-03 |
2015-06-17 |
Novartis AG |
Use of the hdac inhibitor panobinostat for the treatment of myeloma
|
EP1915141A1
(en)
*
|
2005-08-10 |
2008-04-30 |
Novartis AG |
Method of use of deacetylase inhibitors
|
EP1915154A2
(en)
*
|
2005-08-11 |
2008-04-30 |
Novartis AG |
Combination of organic compounds
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
EP1940805A4
(en)
*
|
2005-08-26 |
2009-11-11 |
Methylgene Inc |
BENZODIAZEPIN AND BENZOPIPERAZINANALOGA AS INHIBITORS OF HISTONDEACETYLASE
|
EP2275095A3
(en)
|
2005-08-26 |
2011-08-17 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
WO2007030454A2
(en)
*
|
2005-09-07 |
2007-03-15 |
Novartis Ag |
Mutations and polymorphisms of hdac9
|
WO2007030455A2
(en)
*
|
2005-09-07 |
2007-03-15 |
Novartis Ag |
Mutations and polymorphisms of hdac10
|
WO2007038073A2
(en)
*
|
2005-09-22 |
2007-04-05 |
Novartis Ag |
Mutations and polymorphisms of hdac11
|
AU2006294850A1
(en)
|
2005-09-27 |
2007-04-05 |
Novartis Ag |
Carboxyamine compounds and their use in the treatment of HDAC dependent diseases
|
JP2009512711A
(ja)
|
2005-10-21 |
2009-03-26 |
ブレインセルス,インコーポレイティド |
Pde阻害による神経新生の調節
|
WO2007047998A2
(en)
*
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Mutations and polymorphisms of hdac2
|
EP1942882A2
(en)
*
|
2005-10-24 |
2008-07-16 |
Novartis AG |
Combination of histone deacetylase inhibitors and radiation
|
CA2625210A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
WO2007053502A2
(en)
*
|
2005-11-01 |
2007-05-10 |
Novartis Ag |
Mutations and polymorphisms of hdac5
|
WO2007058992A2
(en)
*
|
2005-11-14 |
2007-05-24 |
Novartis Ag |
Mutations and polymorphisms of hdac6
|
ES2481671T3
(es)
|
2005-11-21 |
2014-07-31 |
Novartis Ag |
Inhibidores de mTOR en el tratamiento de tumores endocrinos
|
US20070207950A1
(en)
*
|
2005-12-21 |
2007-09-06 |
Duke University |
Methods and compositions for regulating HDAC6 activity
|
JP2009525955A
(ja)
*
|
2006-01-13 |
2009-07-16 |
タケダ サン ディエゴ インコーポレイテッド |
ヒストンデアセチラーゼ阻害剤
|
WO2007091703A1
(en)
|
2006-02-07 |
2007-08-16 |
Astellas Pharma Inc. |
N-hydroxyacrylamide compounds
|
AU2007345292B2
(en)
*
|
2006-02-14 |
2013-10-31 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional histone deacetylase inhibitors
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
EP2591775A1
(en)
|
2006-04-05 |
2013-05-15 |
Novartis AG |
Combinations comprising mtor inhibitors for treating cancer
|
MX2008012728A
(es)
|
2006-04-05 |
2008-10-14 |
Novartis Ag |
Combinaciones de agentes terapeuticos para el tratamiento de cancer.
|
ES2637592T3
(es)
|
2006-04-14 |
2017-10-13 |
Cell Signaling Technology, Inc. |
Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
|
US8168383B2
(en)
|
2006-04-14 |
2012-05-01 |
Cell Signaling Technology, Inc. |
Gene defects and mutant ALK kinase in human solid tumors
|
WO2008013589A2
(en)
|
2006-04-24 |
2008-01-31 |
Gloucester Pharmaceuticals |
Treatment of ras-expressing tumors
|
US20090018142A9
(en)
*
|
2006-05-02 |
2009-01-15 |
Zhengping Zhuang |
Use of phosphatases to treat tumors overexpressing N-CoR
|
JP2009536667A
(ja)
|
2006-05-09 |
2009-10-15 |
ブレインセルス,インコーポレイティド |
5ht受容体介在性の神経新生
|
JP2009536180A
(ja)
|
2006-05-09 |
2009-10-08 |
ノバルティス アクチエンゲゼルシャフト |
鉄キレート剤と抗新生物剤を含む組合せ剤およびそれらの使用
|
AU2007249399A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
US8957027B2
(en)
|
2006-06-08 |
2015-02-17 |
Celgene Corporation |
Deacetylase inhibitor therapy
|
UA95289C2
(en)
*
|
2006-06-12 |
2011-07-25 |
Новартис Аг |
Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
|
DK2032531T3
(en)
*
|
2006-06-12 |
2016-04-11 |
Novartis Ag |
Salts of N-hydroxy-3- [4 - [[[2- (2-methyl-1H-indol-3-yl) ethyl] amino] methyl] phenyl] -2E-2-propenamide
|
KR20090015968A
(ko)
*
|
2006-06-12 |
2009-02-12 |
노파르티스 아게 |
N-히드록시-3-[4-[[[2-(2-메틸-1h-인돌-3-일)에틸]아미노]메틸]페닐]-2e-2-프로펜아미드의 동질이상체
|
WO2007146718A2
(en)
*
|
2006-06-12 |
2007-12-21 |
Novartis Ag |
Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino] methyl]phenyl]-2e-2-propenamide and starting materials therefor
|
US7989639B2
(en)
*
|
2006-06-12 |
2011-08-02 |
Novartis Ag |
Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
|
WO2008002862A1
(en)
*
|
2006-06-26 |
2008-01-03 |
Novartis Ag |
Organic compounds
|
KR20090064418A
(ko)
|
2006-09-08 |
2009-06-18 |
브레인셀즈 인코퍼레이션 |
4-아실아미노피리딘 유도체 포함 조합물
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
WO2008036046A1
(en)
|
2006-09-20 |
2008-03-27 |
S*Bio Pte Ltd |
IMIDAZO[l,2-a]PYRIDINE HYDROXYMATE COMPOUNDS THAT ARE INHIBITORS OF HISTONE DEACETYLASE
|
WO2008042146A1
(en)
*
|
2006-09-28 |
2008-04-10 |
Merck & Co., Inc. |
Amine base salts of saha and polymorphs thereof
|
CA2664378A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as pi3k lipid kinase inhibitors
|
GB0619753D0
(en)
|
2006-10-06 |
2006-11-15 |
Chroma Therapeutics Ltd |
Enzyme inhibitors
|
BRPI0622100A2
(pt)
|
2006-10-30 |
2011-12-27 |
Chroma Therapeutics Ltd |
hidroxamatos como inibidores de desacetilase de histona
|
CA2669675A1
(en)
*
|
2006-11-10 |
2008-05-15 |
Syndax Pharmaceuticals, Inc. |
Combination of er.alpha.+ ligands and histone deacetylase inhibitors for the treatment of cancer
|
ES2569477T3
(es)
|
2006-12-04 |
2016-05-11 |
Novartis Ag |
Combinación de un inhibidor de HDAC y un antimetabolito
|
CA2671993A1
(en)
*
|
2006-12-15 |
2008-06-26 |
Astellas Pharma Inc. |
N-hydroxyacrylamide compounds
|
US20100292291A1
(en)
*
|
2007-01-10 |
2010-11-18 |
Thitiwan Buranachokpaisan |
Formulations of deacetylase inhibitors
|
CN103788108B
(zh)
|
2007-02-06 |
2017-04-12 |
利克斯特生物技术公司 |
氧杂双环庚烷和氧杂双环庚烯,它们的制备及用途
|
RU2009134223A
(ru)
|
2007-02-15 |
2011-03-20 |
Новартис АГ (CH) |
Комбинация lbh589 с другими терапевтическими средствами, предназначенная для лечения рака
|
WO2008123395A1
(ja)
|
2007-03-28 |
2008-10-16 |
Santen Pharmaceutical Co., Ltd. |
ヒストン脱アセチル化酵素阻害作用を有する化合物を有効成分として含有する眼圧下降剤
|
US9096565B2
(en)
|
2007-04-09 |
2015-08-04 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
CL2008001269A1
(es)
*
|
2007-05-04 |
2008-12-19 |
Novartis Ag |
Uso de un inhibidor de desacetilasa de histona par el tratamiento de canceres gastro intestinales
|
KR20100016376A
(ko)
*
|
2007-05-11 |
2010-02-12 |
노파르티스 아게 |
흑색종의 치료를 위한 hdac 억제제의 용도
|
AU2008260236A1
(en)
*
|
2007-05-30 |
2008-12-11 |
Novartis Ag |
Use of HDAC inhibitors for the treatment of bone destruction
|
US7737175B2
(en)
|
2007-06-01 |
2010-06-15 |
Duke University |
Methods and compositions for regulating HDAC4 activity
|
CA2718472A1
(en)
*
|
2007-08-03 |
2009-02-12 |
Lixte Biotechnology, Inc. |
Use of phosphatases to treat neuroblastomas and medulloblastomas
|
CL2008002786A1
(es)
*
|
2007-09-20 |
2009-05-15 |
Novartis Ag |
Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion.
|
WO2009045440A1
(en)
|
2007-10-01 |
2009-04-09 |
Lixte Biotechnology Holdings, Inc. |
Hdac inhibitors
|
US8450525B2
(en)
*
|
2007-10-22 |
2013-05-28 |
Orchid Chemicals & Pharmaceuticals Limited |
Histone deacetylase inhibitors
|
CN101417967A
(zh)
*
|
2007-10-26 |
2009-04-29 |
浙江海正药业股份有限公司 |
组蛋白去乙酰酶抑制剂、其组合物及其应用
|
US20090131367A1
(en)
*
|
2007-11-19 |
2009-05-21 |
The Regents Of The University Of Colorado |
Combinations of HDAC Inhibitors and Proteasome Inhibitors
|
US20110044952A1
(en)
*
|
2007-11-27 |
2011-02-24 |
Ottawa Health Research Institute |
Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors
|
CA2708281A1
(en)
|
2007-12-11 |
2009-08-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
ITFI20070288A1
(it)
|
2007-12-21 |
2009-06-22 |
A I L Firenze Sezione Autonoma |
Inibitori delle deacetilasi istoniche
|
EP2100879A1
(en)
*
|
2008-03-13 |
2009-09-16 |
4Sc Ag |
Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds
|
EA020114B1
(ru)
|
2008-03-24 |
2014-08-29 |
Новартис Аг |
Производные арилсульфонамида в качестве ингибиторов матриксной металлопротеазы
|
EP2628726A1
(en)
*
|
2008-03-26 |
2013-08-21 |
Novartis AG |
Hydroxamate-based inhibitors of deacetylases b
|
MX2011000719A
(es)
*
|
2008-07-18 |
2011-03-01 |
Novartis Ag |
Uso de inhibidores de desacetilasa de histona (hdac) para el tratamiento de enfermedad de hodgkin.
|
CA2731730C
(en)
|
2008-07-23 |
2017-06-13 |
President And Fellows Of Harvard College |
Deacetylase inhibitors and uses thereof
|
WO2010014141A1
(en)
*
|
2008-08-01 |
2010-02-04 |
Lixte Biotechnology, Inc. |
Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
|
AU2009277086B2
(en)
*
|
2008-08-01 |
2015-12-10 |
Lixte Biotechnology, Inc. |
Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
|
US8227473B2
(en)
|
2008-08-01 |
2012-07-24 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
|
WO2010147612A1
(en)
|
2009-06-18 |
2010-12-23 |
Lixte Biotechnology, Inc. |
Methods of modulating cell regulation by inhibiting p53
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
TW201031406A
(en)
|
2009-01-29 |
2010-09-01 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
GB0903480D0
(en)
|
2009-02-27 |
2009-04-08 |
Chroma Therapeutics Ltd |
Enzyme Inhibitors
|
KR101168801B1
(ko)
|
2009-03-27 |
2012-07-25 |
주식회사종근당 |
신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
|
ES2473792T3
(es)
|
2009-04-03 |
2014-07-07 |
Naturewise Biotech & Medicals Corporation |
Compuestos cin�micos y derivados de los mismos para la inhibición de la histona desacetilasa
|
US7994357B2
(en)
|
2009-04-03 |
2011-08-09 |
Naturewise Biotech & Medicals Corporation |
Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
|
EP2454267A2
(en)
|
2009-07-16 |
2012-05-23 |
Royal College of Surgeons in Ireland |
Metal complexes having dual histone deacetylase inhibitory and dna-binding activity
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
WO2011019393A2
(en)
*
|
2009-08-11 |
2011-02-17 |
President And Fellows Of Harvard College |
Class- and isoform-specific hdac inhibitors and uses thereof
|
CA2770873A1
(en)
|
2009-08-12 |
2011-02-17 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
IN2012DN01961A
( )
|
2009-08-17 |
2015-08-21 |
Intellikine Llc |
|
EP2467383A1
(en)
|
2009-08-20 |
2012-06-27 |
Novartis AG |
Heterocyclic oxime compounds
|
US20120149661A1
(en)
|
2009-08-26 |
2012-06-14 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
AR077975A1
(es)
|
2009-08-28 |
2011-10-05 |
Irm Llc |
Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
|
US20110053925A1
(en)
*
|
2009-08-28 |
2011-03-03 |
Novartis Ag |
Hydroxamate-Based Inhibitors of Deacetylases
|
MY156209A
(en)
|
2009-11-04 |
2016-01-29 |
Novartis Ag |
Heterocyclic sulfonamide derivatives useful mek inhibitors
|
CN102781237A
(zh)
|
2009-11-23 |
2012-11-14 |
天蓝制药公司 |
用于传递治疗剂的基于环糊精的聚合物
|
EP2509964B1
(en)
|
2009-12-08 |
2014-04-30 |
Novartis AG |
Heterocyclic sulfonamide derivatives
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
WO2011084991A2
(en)
*
|
2010-01-08 |
2011-07-14 |
President And Fellows Of Harvard College |
Fluorinated hdac inhibitors and uses thereof
|
US8981084B2
(en)
|
2010-01-13 |
2015-03-17 |
Tempero Pharmaceuticals, Inc. |
Oxadiazole HDAC inhibitors
|
AU2011205283B2
(en)
|
2010-01-13 |
2014-07-10 |
Tempero Pharmaceuticals, Inc. |
Compounds and methods
|
US20110178287A1
(en)
|
2010-01-19 |
2011-07-21 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
UY33236A
(es)
|
2010-02-25 |
2011-09-30 |
Novartis Ag |
Inhibidores dimericos de las iap
|
US8217079B2
(en)
|
2010-03-26 |
2012-07-10 |
Italfarmaco Spa |
Method for treating Philadelphia-negative myeloproliferative syndromes
|
WO2011119995A2
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc. |
Formulations and methods of use
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
EP2407164A1
(en)
|
2010-07-14 |
2012-01-18 |
Dublin Institute of Technology Intellectual Property Ltd |
Copper II complexes of phenanthroline and their use in cancer treatment
|
WO2012025701A1
(en)
*
|
2010-08-25 |
2012-03-01 |
Chroma Therapeutics Ltd. |
Alpha, alpha - di substituted glycine ester derivatives and their use as hdac inhibitors
|
WO2012025155A1
(en)
*
|
2010-08-26 |
2012-03-01 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases
|
JP2013536207A
(ja)
*
|
2010-08-27 |
2013-09-19 |
ノバルティス アーゲー |
ヒドロキサメート骨格のデアセチラーゼ類阻害剤
|
CN103261186A
(zh)
|
2010-12-13 |
2013-08-21 |
诺瓦提斯公司 |
二聚化iap抑制剂
|
UY33794A
(es)
|
2010-12-13 |
2012-07-31 |
Novartis Ag |
Inhibidores diméricos de las iap
|
WO2012097013A1
(en)
|
2011-01-10 |
2012-07-19 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
TW201245115A
(en)
*
|
2011-01-24 |
2012-11-16 |
Chdi Foundation Inc |
Histone deacetylase inhibitors and compositions and methods of use thereof
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
JP5808826B2
(ja)
|
2011-02-23 |
2015-11-10 |
インテリカイン, エルエルシー |
複素環化合物およびその使用
|
US9295673B2
(en)
|
2011-02-23 |
2016-03-29 |
Intellikine Llc |
Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
|
ES2842970T3
(es)
|
2011-03-09 |
2021-07-15 |
Cereno Scient Ab |
Compuestos y métodos para mejorar la fibrinólisis endógena alterada usando inhibidores de la histona desacetilasa
|
MX2013014398A
(es)
|
2011-06-09 |
2014-03-21 |
Novartis Ag |
Derivados de sulfonamida heterociclicos.
|
CN103608012A
(zh)
|
2011-06-14 |
2014-02-26 |
诺华股份有限公司 |
在癌症如骨髓增殖性肿瘤治疗中的帕比司他与鲁索利替尼的组合
|
EP2721008B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
|
EP2721007B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Cyclohexyl isoquinolinone compounds
|
WO2013001445A1
(en)
|
2011-06-27 |
2013-01-03 |
Novartis Ag |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
ES2691650T3
(es)
|
2011-09-15 |
2018-11-28 |
Novartis Ag |
3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
|
CA2855243C
(en)
|
2011-11-11 |
2020-04-14 |
Novartis Ag |
Method of treating a proliferative disease
|
LT2782557T
(lt)
|
2011-11-23 |
2018-12-27 |
Array Biopharma, Inc. |
Farmacinės kompozicijos
|
CN103130673B
(zh)
*
|
2011-11-28 |
2017-05-03 |
重庆医药工业研究院有限责任公司 |
一种阿戈美拉晶型i的制备方法
|
WO2013080141A1
(en)
|
2011-11-29 |
2013-06-06 |
Novartis Ag |
Pyrazolopyrrolidine compounds
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
EP2794594A1
(en)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Quinoline derivatives
|
PL2794600T3
(pl)
|
2011-12-22 |
2018-06-29 |
Novartis Ag |
Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
|
CA2859869A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
MX2014007731A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
|
EA201491259A1
(ru)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания
|
BR112014015308A2
(pt)
|
2011-12-23 |
2017-06-13 |
Novartis Ag |
compostos para inibição da interação de bcl2 com contrapartes de ligação
|
US9126980B2
(en)
|
2011-12-23 |
2015-09-08 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
JP2015504056A
(ja)
*
|
2011-12-29 |
2015-02-05 |
ファーマサイクリックス,インク. |
ヒストンデアセチラーゼ8の阻害剤としての珪皮酸ヒドロキシアミド
|
EP2802608A4
(en)
|
2012-01-12 |
2015-08-05 |
Univ Yale |
COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY E3 UBIQUITIN LIGASE
|
JO3357B1
(ar)
|
2012-01-26 |
2019-03-13 |
Novartis Ag |
مركبات إيميدازوبيروليدينون
|
TWI573792B
(zh)
|
2012-02-01 |
2017-03-11 |
歐陸斯迪公司 |
新穎治療劑
|
RU2660354C2
(ru)
|
2012-04-03 |
2018-07-05 |
Новартис Аг |
Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
|
WO2013171642A1
(en)
|
2012-05-15 |
2013-11-21 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
|
SI2861579T1
(en)
|
2012-05-15 |
2018-05-31 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
|
AU2013261128B2
(en)
|
2012-05-15 |
2015-11-12 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
|
BR112014027584B1
(pt)
|
2012-05-15 |
2023-01-24 |
Novartis Ag |
Uso de inibidores da atividade de abl1, abl2 e bcr-abl1, e composição farmacêutica
|
JP6171003B2
(ja)
|
2012-05-24 |
2017-07-26 |
ノバルティス アーゲー |
ピロロピロリジノン化合物
|
JP6427097B2
(ja)
|
2012-06-15 |
2018-11-21 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
癌を処置するための組成物および該組成物を製造するための方法
|
AR091773A1
(es)
|
2012-07-16 |
2015-02-25 |
Chdi Foundation Inc |
Inhibidores de la histona desacetilasa y composiciones y sus metodos de uso
|
EP2879675B1
(en)
|
2012-08-06 |
2019-11-13 |
Duke University |
Compounds and methods for targeting hsp90
|
NZ706635A
(en)
|
2012-10-02 |
2018-08-31 |
Gilead Sciences Inc |
Inhibitors of histone demethylases
|
ES2774296T3
(es)
|
2012-10-30 |
2020-07-20 |
Mei Pharma Inc |
Terapias de combinación para tratar cánceres quimiorresistentes
|
CN105377288B
(zh)
|
2012-11-05 |
2019-11-15 |
达纳-法伯癌症研究所股份有限公司 |
Xbp1、cd138和cs1肽的组合物制备药物的用途
|
US20150283136A1
(en)
|
2012-11-08 |
2015-10-08 |
Novartis Ag |
Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
US9403827B2
(en)
|
2013-01-22 |
2016-08-02 |
Novartis Ag |
Substituted purinone compounds
|
EP2948453B1
(en)
|
2013-01-22 |
2017-08-02 |
Novartis AG |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
SG11201506717UA
(en)
|
2013-02-27 |
2015-09-29 |
Epitherapeutics Aps |
Inhibitors of histone demethylases
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
US11491154B2
(en)
|
2013-04-08 |
2022-11-08 |
Dennis M. Brown |
Therapeutic benefit of suboptimally administered chemical compounds
|
AU2014251087B2
(en)
|
2013-04-09 |
2019-05-02 |
Lixte Biotechnology, Inc. |
Formulations of oxabicycloheptanes and oxabicycloheptenes
|
NZ712696A
(en)
*
|
2013-04-29 |
2016-07-29 |
Chong Kun Dang Pharm Corp |
Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
KR20160104612A
(ko)
|
2013-07-26 |
2016-09-05 |
업데이트 파마 인코포레이트 |
비산트렌의 치료 효과 개선용 조성물
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
BR112016003229A8
(pt)
|
2013-09-22 |
2020-02-04 |
Calitor Sciences Llc |
composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
CN103467359B
(zh)
*
|
2013-09-27 |
2015-04-22 |
山东大学 |
一种含有吲哚的肉桂酰胺类组蛋白去乙酰化酶抑制剂及其制备方法和应用
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
CN103664734B
(zh)
*
|
2013-12-10 |
2015-09-23 |
广州康缔安生物科技有限公司 |
杂环羟肟酸类化合物及其药用组合物和应用
|
CN105940001B
(zh)
|
2013-12-12 |
2018-02-06 |
株式会社钟根堂 |
作为选择性组蛋白脱乙酰酶(hdac)抑制剂的新型氮杂吲哚衍生物及包含其的药物组合物
|
KR101685639B1
(ko)
|
2014-01-03 |
2016-12-12 |
주식회사 종근당 |
신규한 인돌 유도체 화합물 및 이를 포함하는 약제학적 조성물
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CN106661039B
(zh)
|
2014-02-28 |
2019-09-13 |
林伯士拉克许米公司 |
酪氨酸蛋白质激酶2(tyk2)抑制剂和其用途
|
US10000469B2
(en)
|
2014-03-25 |
2018-06-19 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
WO2015148867A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
EP3126345A1
(en)
|
2014-03-31 |
2017-02-08 |
Gilead Sciences, Inc. |
Inhibitors of histone demethylases
|
WO2015153345A1
(en)
|
2014-04-03 |
2015-10-08 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
KR20210132233A
(ko)
|
2014-04-14 |
2021-11-03 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
|
GB201409471D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409488D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409485D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
CN107207510B
(zh)
|
2014-07-31 |
2019-11-29 |
诺华股份有限公司 |
联合疗法
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
WO2016023082A1
(en)
|
2014-08-12 |
2016-02-18 |
Monash University |
Lymph directing prodrugs
|
WO2016033169A1
(en)
|
2014-08-27 |
2016-03-03 |
Epitherapeutics Aps |
Compounds and methods for inhibiting histone demethylases
|
EP2995630A1
(en)
|
2014-09-09 |
2016-03-16 |
Dublin Institute of Technology |
Hybrid compounds formed from ionic liquids and uses thereof in ion selective electrodes
|
WO2016040882A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of egfr inhibitors
|
EP3200775B1
(en)
|
2014-10-03 |
2019-11-20 |
Novartis AG |
Combination therapies
|
WO2016138352A1
(en)
|
2015-02-27 |
2016-09-01 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
WO2016145102A1
(en)
|
2015-03-10 |
2016-09-15 |
Aduro Biotech, Inc. |
Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
|
MX2017011778A
(es)
|
2015-03-13 |
2017-12-04 |
Forma Therapeutics Inc |
Compuestos y composiciones de alfa-cinamida como inhibidores de histona desacetilasa 8 (hdac8).
|
EP3297992B1
(en)
|
2015-05-22 |
2020-02-05 |
Chong Kun Dang Pharmaceutical Corp. |
Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
|
WO2017004133A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
CA2995036A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation
|
WO2017032281A1
(zh)
*
|
2015-08-21 |
2017-03-02 |
苏州晶云药物科技有限公司 |
帕比司他乳酸盐的新晶型
|
EP4327809A3
(en)
|
2015-09-02 |
2024-04-17 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
AU2016318229A1
(en)
|
2015-09-08 |
2018-03-29 |
Monash University |
Lymph directing prodrugs
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
SI3364958T1
(sl)
|
2015-10-23 |
2023-05-31 |
Navitor Pharmaceuticals, Inc. |
Modulatorji interakcije sestrina in gator2 ter njihova uporaba
|
US9938264B2
(en)
|
2015-11-02 |
2018-04-10 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
ITUB20155193A1
(it)
|
2015-11-03 |
2017-05-03 |
Italfarmaco Spa |
Sospensioni orali di Givinostat fisicamente e chimicamente stabili
|
CN109069486A
(zh)
|
2015-12-14 |
2018-12-21 |
X4 制药有限公司 |
治疗癌症的方法
|
ES2907489T3
(es)
|
2015-12-14 |
2022-04-25 |
X4 Pharmaceuticals Inc |
Métodos para el tratamiento del cáncer
|
EP3389664A4
(en)
|
2015-12-14 |
2020-01-08 |
Raze Therapeutics Inc. |
MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
|
CN108883091A
(zh)
|
2015-12-22 |
2018-11-23 |
X4 制药有限公司 |
用于治疗免疫缺陷病的方法
|
CN105732467A
(zh)
*
|
2016-01-13 |
2016-07-06 |
深圳市康立生生物科技有限公司 |
一种panobinostat(帕比司他)的制备方法
|
WO2017156179A1
(en)
|
2016-03-09 |
2017-09-14 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
WO2017156165A1
(en)
|
2016-03-09 |
2017-09-14 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
SG11201807972YA
(en)
|
2016-03-15 |
2018-10-30 |
Oryzon Genomics Sa |
Combinations of lsd1 inhibitors for the treatment of hematological malignancies
|
KR102511024B1
(ko)
|
2016-03-15 |
2023-03-16 |
오리존 지노믹스 에스.에이. |
고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
|
JP2019510785A
(ja)
|
2016-04-08 |
2019-04-18 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
癌を処置する方法
|
WO2017184956A1
(en)
|
2016-04-22 |
2017-10-26 |
Duke University |
Compounds and methods for targeting hsp90
|
AR108257A1
(es)
|
2016-05-02 |
2018-08-01 |
Mei Pharma Inc |
Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
EP3454856A4
(en)
|
2016-05-10 |
2019-12-25 |
C4 Therapeutics, Inc. |
HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
WO2017197036A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
AU2017280099A1
(en)
*
|
2016-06-21 |
2019-01-17 |
The University Of Melbourne |
Activators of HIV latency
|
US11332470B2
(en)
|
2016-06-21 |
2022-05-17 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
CN116554168A
(zh)
|
2016-06-21 |
2023-08-08 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
CA3027495A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
WO2018015493A1
(en)
|
2016-07-20 |
2018-01-25 |
Royal College Of Surgeons In Ireland |
Metal complexes having therapeutic applications
|
WO2018039205A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating breast cancer
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
WO2018054960A1
(en)
|
2016-09-21 |
2018-03-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and treating resistance to chemotherapy in npm-alk(+) alcl
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
AU2016426574B2
(en)
|
2016-10-11 |
2023-07-13 |
Euro-Celtique S.A. |
Hodgkin lymphoma therapy
|
CN109952303B
(zh)
|
2016-10-14 |
2022-10-21 |
林伯士拉克许米公司 |
Tyk2抑制剂及其用途
|
AU2017345736B2
(en)
|
2016-10-21 |
2022-04-07 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
US10414727B2
(en)
|
2016-11-08 |
2019-09-17 |
Navitor Pharmaceuticals, Inc. |
Phenyl amino piperidine mTORC inhibitors and uses thereof
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
CN110603261A
(zh)
|
2016-12-23 |
2019-12-20 |
拜斯科阿迪有限公司 |
具有新型键结构的肽衍生物
|
EP3565638B8
(en)
|
2017-01-06 |
2024-04-10 |
BicycleRD Limited |
Bicycle conjugate for treating cancer
|
EP4119552A1
(en)
|
2017-02-08 |
2023-01-18 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
CA3055209A1
(en)
|
2017-03-08 |
2018-09-13 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors, uses, and methods for production thereof
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
JOP20180036A1
(ar)
|
2017-04-18 |
2019-01-30 |
Vifor Int Ag |
أملاح لمثبطات فروبورتين جديدة
|
US10857196B2
(en)
|
2017-04-27 |
2020-12-08 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
CN107141244B
(zh)
*
|
2017-05-08 |
2019-11-19 |
潍坊医学院 |
吲哚丁酸类组蛋白去乙酰酶抑制剂及其制备方法和应用
|
GB201709403D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating sarcoma
|
GB201709402D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating t-pll
|
GB201709405D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating ovarian cancer
|
GB201709406D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro-Cletique S A |
Compounds for treating TNBC
|
CN111032678A
(zh)
|
2017-06-26 |
2020-04-17 |
拜西克尔德有限公司 |
具有可检测部分的双环肽配体和其用途
|
US11046698B2
(en)
|
2017-07-28 |
2021-06-29 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
KR101977970B1
(ko)
|
2017-08-04 |
2019-05-14 |
중원대학교 산학협력단 |
신규한 벤즈아미드계 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 또는 치료용 약학 조성물
|
US20200283482A1
(en)
|
2017-08-14 |
2020-09-10 |
Bicyclerd Limited |
Bicyclic peptide ligand prr-a conjugates and uses thereof
|
EP3668887A1
(en)
|
2017-08-14 |
2020-06-24 |
Bicyclerd Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
JP7366031B2
(ja)
|
2017-09-22 |
2023-10-20 |
カイメラ セラピューティクス, インコーポレイテッド |
タンパク質分解剤およびそれらの使用
|
EP3461480A1
(en)
|
2017-09-27 |
2019-04-03 |
Onxeo |
Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
|
EP3461488A1
(en)
|
2017-09-27 |
2019-04-03 |
Onxeo |
Combination of a dbait molecule and a hdac inhibitor for treating cancer
|
EP3700575A1
(en)
|
2017-10-24 |
2020-09-02 |
Oncopep, Inc. |
Peptide vaccines and pembrolizumab for treating breast cancer
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
|
EP3700901A1
(en)
|
2017-10-24 |
2020-09-02 |
Genentech, Inc. |
(4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
|
JP7254076B2
(ja)
|
2017-11-19 |
2023-04-07 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッド |
置換ヘテロアリール化合物及び使用方法
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
JP7021356B2
(ja)
|
2017-12-21 |
2022-02-16 |
ヘフェイ インスティテューツ オブ フィジカル サイエンス, チャイニーズ アカデミー オブ サイエンシーズ |
ピリミジン誘導体系キナーゼ阻害剤類
|
JP2021508703A
(ja)
|
2017-12-26 |
2021-03-11 |
カイメラ セラピューティクス, インコーポレイテッド |
Irak分解剤およびそれらの使用
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
WO2019143874A1
(en)
|
2018-01-20 |
2019-07-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
WO2019148136A1
(en)
|
2018-01-29 |
2019-08-01 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
CA3089762A1
(en)
|
2018-01-29 |
2019-08-01 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
IL276608B2
(en)
|
2018-02-12 |
2024-04-01 |
Inimmune Corp |
TOLL-like receptor ligands
|
IL301120A
(en)
|
2018-02-27 |
2023-05-01 |
Artax Biopharma Inc |
A history of novel chromium as TCR–NCK interaction inhibitors
|
WO2019183523A1
(en)
|
2018-03-23 |
2019-09-26 |
Genentech, Inc. |
Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
|
AU2019251223A1
(en)
|
2018-04-13 |
2020-11-26 |
Arvinas Operations, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
AR114828A1
(es)
|
2018-04-24 |
2020-10-21 |
Vertex Pharma |
Compuestos de pteridinona y sus usos
|
TWI813673B
(zh)
|
2018-04-24 |
2023-09-01 |
德商馬克專利公司 |
抗增生化合物及其用途
|
KR20210020107A
(ko)
|
2018-06-13 |
2021-02-23 |
암피스타 테라퓨틱스 엘티디 |
UchL5 표적화를 위한 이중작용성 분자
|
WO2019238886A1
(en)
|
2018-06-13 |
2019-12-19 |
University Of Dundee |
Bifunctional molecules for targeting usp14
|
CA3103185A1
(en)
|
2018-06-13 |
2019-12-19 |
Amphista Therapeutics Ltd |
Bifunctional molecules for targeting rpn11
|
JP7382353B2
(ja)
|
2018-06-15 |
2023-11-16 |
ヤンセン ファーマシューティカ エヌ.ベー. |
ラパマイシン類似体およびその使用
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
CN108752255A
(zh)
*
|
2018-07-19 |
2018-11-06 |
重庆医科大学 |
一种帕比司他及其关键中间体的制备方法
|
EP3826988A4
(en)
|
2018-07-24 |
2023-03-22 |
Hygia Pharmaceuticals, LLC |
COMPOUNDS, DERIVATIVES AND ANALOGS AGAINST CANCER
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
US11414431B2
(en)
|
2018-10-15 |
2022-08-16 |
Nimbus Lakshmi, Inc. |
Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors
|
US10919937B2
(en)
|
2018-10-23 |
2021-02-16 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
CN109574936B
(zh)
*
|
2018-11-23 |
2022-02-22 |
沈阳药科大学 |
一种具有hdac6抑制活性的异羟肟酸类化合物及其应用
|
EP3886843A4
(en)
|
2018-11-30 |
2022-08-31 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND THEIR USES
|
KR20210111252A
(ko)
|
2018-11-30 |
2021-09-10 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
WO2020132561A1
(en)
|
2018-12-20 |
2020-06-25 |
C4 Therapeutics, Inc. |
Targeted protein degradation
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
JP2022518505A
(ja)
|
2019-01-23 |
2022-03-15 |
ニンバス ラクシュミ, インコーポレイテッド |
Tyk2阻害剤およびその使用
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
US20220184222A1
(en)
|
2019-04-02 |
2022-06-16 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
WO2020206424A1
(en)
|
2019-04-05 |
2020-10-08 |
Kymera Therapeutics, Inc. |
Stat degraders and uses thereof
|
CN114502540A
(zh)
|
2019-05-31 |
2022-05-13 |
医肯纳肿瘤学公司 |
Tead抑制剂和其用途
|
GB201913124D0
(en)
|
2019-09-11 |
2019-10-23 |
Seald As |
Compositions and methods for treatment of cholangiocarcinoma
|
GB201913121D0
(en)
|
2019-09-11 |
2019-10-23 |
Seald As |
Compositions and methods for treatment of cholangiocarcinoma
|
JP2022548594A
(ja)
|
2019-09-11 |
2022-11-21 |
ビンシア・バイオサイエンシーズ・インコーポレイテッド |
Usp30阻害剤及びその使用
|
GB201913123D0
(en)
|
2019-09-11 |
2019-10-23 |
Seald As |
Compositions and methods for treatment of cholangiocarcinoma
|
GB201913122D0
(en)
|
2019-09-11 |
2019-10-23 |
Seald As |
Compositions and methods for treatment of cholangiocarcinoma
|
AU2020353221A1
(en)
|
2019-09-25 |
2022-03-31 |
University College Dublin |
Nanoparticle compositions for gene therapy
|
EP3798250A1
(en)
|
2019-09-25 |
2021-03-31 |
University College Dublin |
Hyperbranched cationic polymers useful as nucleic acid delivery vectors for transfecting
|
EP4054546A4
(en)
*
|
2019-11-06 |
2023-10-18 |
Dana-Farber Cancer Institute, Inc. |
SELECTIVE HISTONE DEACETYLASE (HDAC) DEGRADATION PRODUCTS AND METHOD FOR THE USE THEREOF
|
EP4069223A4
(en)
|
2019-12-05 |
2023-12-20 |
Janssen Pharmaceutica NV |
RAPAMYCIN ANALOGS AND THEIR USES
|
TW202136251A
(zh)
|
2019-12-17 |
2021-10-01 |
美商凱麥拉醫療公司 |
Irak降解劑及其用途
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
PE20221582A1
(es)
|
2019-12-19 |
2022-10-06 |
Arvinas Operations Inc |
Compuestos y metodos para la degradacion dirigida de receptor de androgenos
|
BR112022012410A2
(pt)
|
2019-12-23 |
2022-08-30 |
Kymera Therapeutics Inc |
Degradadores smarca e usos dos mesmos
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
EP4100017A4
(en)
|
2020-02-05 |
2024-04-10 |
PureTech LYT, Inc. |
LIPID PRODRUGS OF NEUROSTEROIDS
|
IT202000004075A1
(it)
|
2020-02-27 |
2021-08-27 |
Flamma Spa |
Processo per la preparazione di panobinostat
|
EP4114529A1
(en)
|
2020-03-03 |
2023-01-11 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
IL296451A
(en)
|
2020-03-19 |
2022-11-01 |
Kymera Therapeutics Inc |
mdm2 joints and their uses
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
US20230285576A1
(en)
|
2020-08-05 |
2023-09-14 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
AU2021327130A1
(en)
|
2020-08-17 |
2023-03-02 |
Bicycletx Limited |
Bicycle conjugates specific for Nectin-4 and uses thereof
|
WO2022047259A1
(en)
|
2020-08-28 |
2022-03-03 |
California Institute Of Technology |
Synthetic mammalian signaling circuits for robust cell population control
|
IL303376A
(en)
|
2020-12-02 |
2023-08-01 |
Ikena Oncology Inc |
TEAD inhibitors and their uses
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
CA3201962A1
(en)
|
2020-12-18 |
2022-06-23 |
Andrea TESTA |
Novel bifunctional molecules for targeted protein degradation
|
GB202020359D0
(en)
|
2020-12-22 |
2021-02-03 |
Midatech Pharma Wales Ltd |
Pharmaceutical compositions and use thereof in combination therapy for brain cancer
|
BR112023015590A2
(pt)
|
2021-02-02 |
2023-10-17 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 e usos dos mesmos
|
MX2023009059A
(es)
|
2021-02-02 |
2023-09-15 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
KR20230172548A
(ko)
|
2021-04-16 |
2023-12-22 |
이케나 온콜로지, 인코포레이티드 |
Mek 억제제 및 이의 용도
|
CN118103368A
(zh)
|
2021-08-25 |
2024-05-28 |
皮克医疗公司 |
Eif4e抑制剂及其用途
|
WO2023028238A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2023041805A1
(en)
|
2021-09-20 |
2023-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
|
GB2611043A
(en)
|
2021-09-22 |
2023-03-29 |
Univ Dublin City |
A cis-platinum(II)-oligomer hybrid
|
WO2023089183A1
(en)
|
2021-11-19 |
2023-05-25 |
Branca Bunus Limited |
A composition comprising a therapeutically active agent packaged within a drug delivery vehicle
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023194441A1
(en)
|
2022-04-05 |
2023-10-12 |
Istituto Nazionale Tumori Irccs - Fondazione G. Pascale |
Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
GB2617409B
(en)
|
2022-04-27 |
2024-06-26 |
Cancertain Ltd |
Method for predicting responsiveness to therapy
|
TW202404581A
(zh)
|
2022-05-25 |
2024-02-01 |
美商醫肯納腫瘤學公司 |
Mek抑制劑及其用途
|
WO2023242597A1
(en)
|
2022-06-16 |
2023-12-21 |
Amphista Therapeutics Limited |
Bifunctional molecules for targeted protein degradation
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
TW202415650A
(zh)
|
2022-08-02 |
2024-04-16 |
英商利米那生物科技有限公司 |
芳基-三唑基及相關gpr84拮抗劑及其用途
|
WO2024041744A1
(en)
|
2022-08-26 |
2024-02-29 |
Biodexa Ltd. |
Combination therapy for brain cancer
|
US20240208961A1
(en)
|
2022-11-22 |
2024-06-27 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|